Sound Income Strategies LLC Increases Stake in Pfizer Inc. (NYSE:PFE)

Sound Income Strategies LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 9.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 238,438 shares of the biopharmaceutical company’s stock after purchasing an additional 21,001 shares during the quarter. Pfizer accounts for 1.6% of Sound Income Strategies LLC’s holdings, making the stock its 17th largest position. Sound Income Strategies LLC’s holdings in Pfizer were worth $12,218,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of PFE. Front Street Capital Management Inc. increased its holdings in Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 215 shares during the period. Lindenwold Advisors increased its stake in shares of Pfizer by 1.0% during the third quarter. Lindenwold Advisors now owns 21,151 shares of the biopharmaceutical company’s stock valued at $926,000 after buying an additional 216 shares during the period. SRS Capital Advisors Inc. raised its holdings in shares of Pfizer by 1.6% in the second quarter. SRS Capital Advisors Inc. now owns 13,618 shares of the biopharmaceutical company’s stock valued at $714,000 after acquiring an additional 218 shares in the last quarter. Signet Financial Management LLC lifted its stake in Pfizer by 0.6% in the third quarter. Signet Financial Management LLC now owns 34,338 shares of the biopharmaceutical company’s stock worth $1,503,000 after acquiring an additional 220 shares during the period. Finally, Mitchell Mcleod Pugh & Williams Inc. grew its holdings in Pfizer by 0.7% during the 3rd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 33,978 shares of the biopharmaceutical company’s stock worth $1,487,000 after acquiring an additional 222 shares in the last quarter. Hedge funds and other institutional investors own 67.62% of the company’s stock.

Pfizer Trading Down 0.7 %

NYSE PFE opened at $40.10 on Friday. Pfizer Inc. has a 12-month low of $39.23 and a 12-month high of $56.32. The company has a fifty day simple moving average of $43.26 and a two-hundred day simple moving average of $46.03. The company has a current ratio of 1.22, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34. The stock has a market cap of $225.33 billion, a P/E ratio of 7.32, a P/E/G ratio of 1.35 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last issued its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The company had revenue of $24.30 billion during the quarter, compared to analyst estimates of $24.40 billion. During the same quarter last year, the business posted $1.08 EPS. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. On average, analysts forecast that Pfizer Inc. will post 3.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PFE shares. BMO Capital Markets reduced their price target on shares of Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, February 1st. Atlantic Securities lowered their target price on Pfizer from $50.00 to $46.00 and set a “neutral” rating for the company in a report on Wednesday, February 1st. Barclays reduced their price target on Pfizer from $49.00 to $44.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 1st. Credit Suisse Group dropped their price objective on Pfizer from $54.00 to $50.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $75.00 target price on shares of Pfizer in a report on Wednesday, February 1st. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $50.38.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.